New pill targets rare gene fault in advanced cancers

NCT ID NCT04683250

Recruiting now Disease control Sponsor: Taiho Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called TAS0953/HM06 in people with advanced solid tumors that have specific RET gene abnormalities. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks how well the drug shrinks tumors. About 244 adults with RET-altered non-small cell lung cancer or other solid tumors will take the drug orally twice a day in 21-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAS0953/HM06 (a targeted drug that blocks the RET protein to slow or stop cancer growth)
What this could lead to: If successful, this could provide a new treatment option for people with advanced cancers that have specific RET gene changes, potentially shrinking tumors or slowing disease progression.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not work as hoped or could cause unexpected side effects. Results may not apply to all patients with RET alterations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma RET fusion positive cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RET-ALTERED NON SMALL CELL LUNG CANCER RET-ALTERED SOLID TUMORS

Contacts and locations

Locations

Chao Family Comprehensive Cancer Center
TERMINATED

Orange, California, 92868-3298, United States
Henry Ford Hospital
TERMINATED

Detroit, Michigan, 48202, United States
Kanagawa Cancer Center
RECRUITING

Kanagawa, Japan
Kansai Medical University Hospital
RECRUITING

Hirakata-shi, Osaka, Japan
Kurashiki Central Hospital
RECRUITING

Okayama, Japan
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
TERMINATED

New York, New York, 10016, United States
Massachusetts General Hospital
TERMINATED

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
TERMINATED

New York, New York, 10065, United States
National Cancer Center Hospital
RECRUITING

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa-shi, Chiba, Japan
National Hospital Organization Kyushu Cancer Center
RECRUITING

Fukuoka, Japan
Okayama University Hospital
RECRUITING

Okayama, Okayama-ken, Japan
Osaka International Cancer Institute
RECRUITING

Osaka, Osaka, Japan
START Midwest - Cancer & Hematology Centers of Western Michigan
TERMINATED

Grand Rapids, Michigan, 49546, United States
Samsung Medical Center
RECRUITING

Seoul, South Korea
Shizuoka Cancer Center
RECRUITING

Shizuoka, Shizuoka, Japan
Stanford Cancer Center
TERMINATED

Stanford, California, 94305-5826, United States
The Cancer Institute Hospital of JFCR
RECRUITING

Koto-ku, Tokyo, 135-8550, Japan
The Sarah Cannon Research Institute/Tennessee Oncology
TERMINATED

Nashville, Tennessee, 37203, United States
The University of Texas M. D. Anderson Cancer Center
TERMINATED

Houston, Texas, 77030-4009, United States
Tohoku University Hospital
RECRUITING

Sendai, Miyagi, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.